As pharmaceutical companies have reported their earnings over the past two weeks, it’s been like staring at a foreboding sky, guessing: Will it merely drizzle? Or will there be a storm, and a flood?
The reason? Worries about drug prices. What else. As Pfizer’s new chief executive, Albert Bourla, said during a question-and-answer session with analysts: It’s “very clear that pricing is not going to be a growth driver for us now and, I think, in the future. It’s very clear.”